In June 2024, four altcoins stand out as promising investments with the potential for maximum returns: Bitgert (BRISE), Solana (SOL), Injective (INJ), and NEAR Protocol (NEAR).

Bitgert aims to revolutionize decentralized finance (DeFi) with its scalable blockchain infrastructure that supports fast, low-cost transactions. Its focus on interoperability and user-friendly applications has garnered attention, and as DeFi continues to expand, Bitgert's innovative solutions could attract significant interest.

Solana has positioned itself as a high-performance blockchain for decentralized applications (dApps) and crypto projects that require fast transaction speeds and low costs. Its unique proof-of-history (PoH) consensus combined with proof-of-stake (PoS) has enabled Solana to handle a large volume of transactions efficiently, making it a strong candidate for investors seeking long-term growth.

Injective focuses on decentralized derivatives trading, allowing users to trade a wide range of assets without relying on intermediaries. By leveraging a Layer-2 protocol, Injective offers fast transaction speeds and low fees, making it attractive for both institutional and retail traders. As the derivatives market expands, Injective Protocol's decentralized approach could drive substantial adoption and value appreciation.

NEAR Protocol aims to make blockchain technology accessible and usable for developers and end-users alike through its scalable, developer-friendly platform. NEAR's emphasis on usability and innovation has led to partnerships with various projects and developers, fostering a vibrant ecosystem of decentralized applications. As the demand for scalable blockchain solutions grows, NEAR Protocol's user-friendly approach could lead to significant growth in its ecosystem and token value.

Investing in altcoins involves inherent risks, and thorough research on each project's fundamentals, team expertise, market traction, and technological advancements is crucial before making investment decisions. While Bitgert, Solana, Injective, and NEAR Protocol present compelling opportunities in June 2024, investors should assess their risk tolerance and investment goals accordingly.